Work

10P HER2 loss and PAM50 dynamics after neoadjuvant therapy (NAT) in HER2-positive (HER2+) early breast cancer (BC)

Year: 2023

Type: article

Abstract: HER2 loss on residual disease (RD) is frequent after NAT. Subtype switch has been also reported, with HER2-Enriched (HER2E) tumors converting frequently to non-HER2E. However, the association between HER2 immunohistochemistry (IHC) status and intrinsic subtype (IS) has never been described.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2023.101234

Authors: S. Morganti, F. Brasó-Maristany, M. Rey, G. Goberna, T. Pascual, F. Schettini, B. Conte, R. Gomez Bravo, I. Garcia Fructuoso, E. Segui Solis, P. Galván, E. Sanfeliu Torres, B. Gonzalez-Farre, M.J. Vidal Losada, B. Adamo, M. Munoz, N. Lin, S.M. Tolaney, A. Prat, O. Martinez Saez

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Hospital Clínic de Barcelona

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,290

OpenAlex ID: W4381938303

FWCI:

Cites: 1

Cited by:

Related to: 10